The MTG (Myeloid Translocation Gene) proteins are a family of novel transcriptional corepressors. We report that MTG16a, a protein isoform encoded by the MTG16 gene deranged by the t (16; 21) in myeloid malignancies, is targeted to the nucleolus. The amino acid sequence necessary for nucleolar localization was mapped to the MTG16a N-terminal region. MTG16a, like MTG8, the nuclear corepressor deranged by the t (8; 21), is capable to interact with specific histone deacetylases (HDACs) suggesting that the protein may mediate silencing of nucleolar gene transcription. In addition, MTG16a is capable to form oligomers with other MTG proteins. As a consequence of the t (16; 21) the AML1 DNA-binding domain replaces the MTG16a N-terminal region. The AML1-MTG16 fusion protein is targeted to the nucleoplasm where it is capable to oligomerize with MTG16a and interact with HDAC1 and HDAC3. The deficiency of HDAC-containing complexes at nucleolar sites and the accumulation of HDAC-containing complexes at AML1-sites may be critical in the pathogenesis of t (16; 21) myeloid malignancies.
Introduction
The human MTG genes and their mouse counterparts probably originated from a common ancestor gene (Morohoshi et al., 2000) , evolutionarily related to the Drosophila gene nervy. The genes encode a novel class of transcriptional corepressors (Gelmetti et al., 1998; Lutterbach et al., 1998a; Wang et al., 1998) and are implicated both in leukemia (Downing, 1999) and neurodegenerative disorders (Wood et al., 2000) .
As a consequence of non-random chromosome translocations found in human leukemia, MTG8 (also ETO/CDR) (Erickson et al., 1992; Miyoshi et al., 1993; Nisson et al., 1992) and MTG16/MTGR2 (Calabi and Cilli, 1998; Gamou et al., 1998) rearrange with AML1, which encodes a transcription factor crucial for definitive hematopoiesis (see Downing, 1999 and references within). There is mounting evidence that MTG8 acts as a transcriptional corepressor. MTG8 is unable to bind to DNA directly but can interact with nuclear corepressor proteins, N-CoR, SMRT and Sin 3A (Wang et al., 1998; Gelmetti et al., 1998; Lutterbach et al., 1998a; Melnick et al., 2000; ) as well as with different histone deacetylases (HDACs) (Amann et al., 2001) . The high degree of similarity over four major functional domains, NHR1-NHR4 (Davis et al., 1999; Feinstein et al., 1995; Gross and McGinnis, 1996; Kitabayashi et al., 1998; Lutterbach et al., 1998b) suggests that human MTG16 and MTGR1 and their murine counterparts (Davis et al., 1999; Amann et al., 2001 ) also act as nuclear co-repressors.
The leukemic proteins AML1-MTG8 and AML1-MTG16 retain domains of AML1 and either MTG8 or MTG16, including the NHR2 and NHR4 domains for dimerization and corepressor recruitment. The AML1-MTG8 protein likely induces hematopoietic transformation via a variety of mechanisms including dominant interference with the normal transactivation function of AML1, deregulation of specific target genes, inhibition of transcription of genes regulated by other transcription factors (Downing, 1999) and possibly oligomerization with MTG8 and other MTGs (Melnick et al., 2000; Shimada et al., 2000; Minucci et al., 2000; Hildebrand et al., 2001; Zhang et al., 2001) .
In an attempt to better understand the pathogenesis of AML1-MTG16-positive myeloid malignancies we set out to study the intranuclear localization and properties of the normal and chimeric MTG16 isoforms. Here we show that despite the striking similarity to MTG8 and MTGR1, which are localized in the nucleoplasm, MTG16a is targeted to the nucleolus. The amino acid sequence necessary for nucleolar targeting is located in the N-terminal region. The first three exons encoding this region are replaced by the runt sequence encompassing the DNA-binding domain of AML1 in the AML1-MTG16, which is targeted to the nucleoplasm where it can heterodimerize with MTG16a. MTG16a can interact with HDAC1 and HDAC3 suggesting a transcriptional corepressor function in the nucleolus. The same HDACs can interact with AML1-MTG16 in the nucleoplasm. Thus, the t (16; 21) may result in the deficiency of a nucleolar MTG16a-HDAC-repressive complex at nucleolar sites and an accumulation of HDAC-complexes mediated by AML1-MTG16 at sites harboring genes normally regulated by AML1.
Results

Detection of the MTG16, MTGR1 and MTG8 proteins
We raised three anti-peptide antibodies AB-8, AB-16, AB-R1 ( Figure 1a ) against unique regions of the three MTG proteins. We also used AB-V5 directed against the V5-tag to detect MTG16a-V5, MTG16b-V5 and MTGR1a-V5 (Figure 1b) . The specificity of AB-8, AB-16 and AB-R1 was determined in Western blotting experiments ( Figure 1b ) and combined immunoprecipitation (IP) and Western blotting (WB) experiments on COS cells over-expressing MTG8b, MTG16a-V5 and MTGR1-V5 respectively (Figure 1c ).
Western blotting of HEL and Kasumi-1 cell lines with AB-8 detected the endogenous MTG8 and AML1-MTG8 proteins comparable, in size, to the over-expressed MTG8 and AML1-MTG8 proteins (Figure 1d ). These data fully support our previous protein findings (Sacchi et al., 1996 (Sacchi et al., , 1998 . In contrast, we could not detect either endogenous MTG16a or MTGR1a proteins in any hematopoietic cell line, which we screened so far (data not shown), even when we amplified the corresponding transcripts by RT -PCR (Figure 2g ).
The wild type MTG16a protein is targeted to the nucleolus
By immunocytochemistry (IC) of COS cells transfected with different MTG expression vectors (Gateway-CMV-MTG8b, pcDNA3.1-MTG16a-V5 or pcDNA3.1-MTGR1a-V5), we found that MTG16a was targeted to 'nuclear bodies', while MTG8b and MTGR1a were targeted to the nucleoplasm (Figure 1e ). MTG16a was localized in nuclear bodies also in CSM14.1, a rat neuronal-like cell line, in HeLa, an epithelial cell line and human fibroblasts (Figure 1e ). In vivo time-lapse imaging of COS cells over-expressing MTG16a-GFP showed that after being translated in the cytoplasm, MTG16a enters the nucleoplasm, aggregates in multiple particles to form one (or more) nuclear body (Figure 1f ). The sequence of events resembles a process called nucleolar fusion, where multiple small nucleoli appear to fuse into one, or more, large nucleoli (Anastassova-Kristeva, 1977).
The supposition that the nuclear bodies are nucleoli is supported by the co-localization of MTG16a with the nucleolar protein B23 (Figure 1g ). We often observed that MTG16a could accumulate at the periphery of the nucleolus and in some nucleoli (Figure 1g ).
The MTG16a N-terminal region is necessary for nucleolar targeting
Comparison of the protein domains and amino acid sequences of the nucleoplasmic MTG8, MTGR1 isoforms (Figure 1a) , the nucleoplasmic MTG16b (Figure 2a) , and the nucleolar MTG16a (Figure 2a ) suggested to us that the putative nucleolar localization signal is contained in the MTG16a N-terminal region encompassing the first three exons. For this reason, we developed two deletion mutants MTG16D1, MTG16D2 (see sequence in Figure 2a ). MTG16D1, missing the first 61 amino acids (aa) encoded by exon 1a and part of exon 2, co-localized with B23 ( Figure 2c ). In contrast, MTG16D2, lacking the first 127 aa encompassing exons 1a-3, failed to localize in the nucleolus and aggregated in small nuclear bodies, which did not co-localize with B23 ( Figure 2d ). This latter observation was confirmed in vivo by time-lapse imaging of COS cells transfected with MTG16D2-GFP (Figure 2f ). These data indicated that the aa sequence necessary for nucleolar localization is indeed contained in this Nterminal region. Because D2-GFP, containing the first three exons of MTG16a coupled to GFP failed to target the nucleolus (Figure 2e ), we conclude that the MTG16a N-terminal region contains a domain, which is necessary, but not sufficient, for nucleolar targeting.
Detection of in-frame and out-of-frame splice forms encoding different N-termini When we analysed a few leukemic cell lines for the expression of MTG16a and other MTG transcripts we found that each cell line displays a specific repertoire of MTG transcripts (Figure 2g ). In the course of this analysis, we identified another in-frame alternate MTG16 transcript in KG1a and K562 ( Figure 2g ). DNA sequencing showed that this transcript, which we termed MTG16c, encodes for a protein lacking exons 2 and 3 ( Figure 2a ). In HEL cells we detected another MTG16 transcript (Figure 2g ), which upon sequencing, showed to be an out-of-frame (o.f.) splicing of exon1a onto exon 5 leading to a truncated protein (Figure 2a ).
MTG16a can heterodimerize with MTG8b and MTGR1a and the heterodimers are targeted to the nucleolus
Since MTG16a contains the dimerization domain and seems to be often co-expressed with other MTGs (Figure 2g ), we tested whether MTG16a can heterodimerize with nucleoplasmic MTG isoforms. COS cells transfected with different combinations of MTG expression vectors were analysed by IC as well as by combined IP and WB. When pcDNA3.1-MTG16a-V5 was co-transfected with Gateway-CMV-MTG8b or pLNCX2-MTGR1a, MTG16a apparently dragged both MTG8b and MTGR1a to the nucleolus ( Figure  3a ). When Gateway-CMV-MTG8b was co-transfected with pcDNA3.1-MTGR1a-V5, both MTG8b and MTGR1a remained in the nucleoplasm (Figure 3a ).
IP and WB experiments showed that IC images reflected actual protein -protein interactions ( Figure  3b ). Total homogenates of COS cells co-expressing MTG8b+MTG16a-V5, MTG8b+MTGR1a-V5 and MTGR1a-V5+MTG16a-V5 were immunoprecipitated with either AB-8 (IP AB-8 ) or AB-16 (IP AB-16 ) ( Figure  3b ) and analysed by WB. MTG8b was detected both in the total and IP AB-8 samples of MTG8b+MTG16a-V5 and MTG8b+MTGR1a-V5 using AB-8. No signal (cross-reactive material) was found in the total and IP AB-16 samples of MTGR1a-V5 +MTG16a-V5 (negative control) ( Figure 3b , upper panel). The same blot was stripped and re-probed with AB-V5, which detected MTG16a-V5 and MTGR1-V5 both in the total and IP samples ( Figure 3b , lower panel). Simultaneous comparison of the upper and lower panels clearly shows that MTG16a-V5 and MTGR1a-V5 co-precipitate with MTG8b, and MTGR1a-V5 coprecipitates with MTG16a-V5. Thus, upon heterodimerization with MTG16a, nucleoplasmic MTG isoforms can be targeted to the nucleolus.
MTG16a differs from MTG8b and MTGR1a in the nucleus-cytoplasm shuttling test
Targeting of proteins to specific nuclear sites may be a dynamic process requiring shuttling to the cytoplasm. The interspecies heterokaryon test (Guiochon-Mantel et al., 1991) can give a hint whether this is the case. HeLa cells transfected with the individual MTGs were fused with mouse NIH3T3 cells in the presence of MTG8b (red) and MTGR1a (green) in the nucleoplasm and of MTG16a (red) in 'nuclear bodies'. Exogenous MTG16a-V5 was detected in nuclear bodies also in CSM14.1, HeLa and fibroblasts. (f) Time-lapse imaging of COS cells transiently transfected with MTG16a-GFP shows the dynamic accumulation of MTG16a in nuclear bodies (green). (g) MTG16a-V5 (red) co-localizes with the nucleolar protein B23 (green). MTG16a-V5 targets only some of the B23-positive nucleoli, and is often localized in a ring at the periphery of the nucleolus cycloheximide. Human -mouse heterokaryons were analysed 6 h after fusion by IC. Mouse nuclei were distinguished from human nuclei because of a characteristic dotted appearance, when stained with Hoechst. The control p53 protein was detected both in human and mouse nuclei indicating shuttling properties (Figure 3c ). MTG8b and MTGR1a were detected only in human nuclei (Figure 3c ). In contrast, MTG16a could be identified by AB-16 in the human nucleolus as well as small particles in the mouse nucleus ( Figure 3c ). We do not know whether the particles can aggregate in one, or more, nucleoli, since we did not perform time-lapse imaging of the heterokaryons.
MTG16a can interact with specific HDACs
Recently, it has been shown that the murine homologue of MTG16, mETO-2 is a transcriptional corepressor with features different from MTG8/ETO. For this reason, we tested the co-localization and interaction of MTG16a with three nuclear HDACs, 1, 3 and 4 and the cytoplasmic HDAC6. None of these HDACs co-localized with the nucleolar B23 protein (Figure 4a) . Interaction of MTG16a with HDAC1 and HDAC3 was clearly demonstrated by IP with AB-16 followed by sequential WB with AB-FLAG (Figure 4c , upper panel) and AB-16 (Figure 4c , lower panel) of COS cells co-transfected with MTG16a and specific HDAC-FLAG constructs. Interestingly, MTG16a can specifically interact and drag the nuclear HDAC1 and HDAC3, but not the nuclear HDAC4 to the nucleolus. In contrast to mETO-2 (Amann et al., 2001) , the human MTG16a cannot colocalize/interact with the cytoplasmic HDAC6 (Figure 4b,c) .
AML1-MTG16 targets MTG16a to the nucleoplasm via two related, but distinct mechanisms
Consequent to the t (16; 21), the DNA-binding domain of AML1 can replace the first three exons of MTG16 (Figure 1a ) to form the AML1-MTG16 type1 chimeric protein (Gamou et al., 1998) . This protein is targeted to the nucleoplasm (Figure 5a ). In contrast to t (8; 21)-positive AML, where MTG8 is not co-expressed with the wild-type MTG8a and b (see for example the Kasumi-1 cells, Figure 2g ), in t(16;21)-positive myeloid malignancies the chimeric transcript is co-expressed with both AML1 and the wild-type MTG16 transcripts (Gamou et al., 1998) . For this reason we co-transfected pcDNA3.1-AML1-MTG16-V5 and pcDNA3.1-MTG16a-GFP into COS cells. Interestingly, MTG16a failed to target the nucleolus when co-expressed with AML1-MTG16 (Figure 5b ), due to interaction with the chimeric protein. The interaction was demonstrated in co-transfected cells by sequential immunoblotting analysis of total homogenate and samples immunoprecipitated with AB-V5 (Figure 5c , left) and with AB-GFP (Figure 5c, right) .
In addition, when we co-transfected the AML1-MTG16 protein with HDAC1 and HDAC3, which we formerly saw co-localized with MTG16a in the nucleolus (Figure 4b) , we found that they co-localize in the nucleoplasm (Figure 5d ). This co-localization reflects the interaction between AML1-MTG16 and HDAC1 and HDAC3, respectively as demonstrated by sequential WB analysis of total homogenates and 
Discussion
In this report we show that MTG16a, one of the isoforms encoded by the MTG16 gene affected by the t (16; 21) in myeloid malignancies (Gamou et al., 1998) is targeted to the nucleolus (Figure 1) . The region responsible for nucleolar targeting maps to the Nterminus (Figure 2 ). How MTG16a is targeted to the nucleolus is still unclear. By using deletion mutants, we demonstrated that the N-terminal region of MTG16a, encoding the first three exons, is necessary, but not sufficient for nucleolar targeting (Figure 2) . Interestingly, the 5' sequences of MTG16 seems to be involved in active alternate splicing, which can generate in-frame and out-of-frame MTG16 transcripts. The corresponding proteins may have distinct topography and consequently distinct function. This is likely the case of MTG16b, which lacks exon 3 (Figure 2a,b) and is nucleoplasmic.
We were not able to identify any known, or novel, nucleolar localization signal in the amino acid sequence crucial for nucleolar targeting (Kubota et al., 1999; Siomi et al., 1988; Tamanini et al., 2000) . Thus the targeting of MTG16a to the nucleolus may implicate additional mechanisms, like specific protein folding of the N-terminal region, or the intervention of other nucleolar proteins, as is the case for the nucleolar targeting of nucleolin, which also lacks a nucleolar signal (Schmidt-Zachmann and Nigg, 1993) .
We observed that MTG16a could interact and drag both MTG8 and MTGR1 to the nucleolus (Figure 3a) . Thus, it looks like that the putative MTG16a-nucleolar repressor complex may contain other MTG proteins and be heterogeneous in its MTGs content. This feature might be necessary to perform a fine regulation of nucleolar genes in different cell types. The ability of MTG16a to localize in the nucleolus is not the only difference found so far between MTG16a and other MTG proteins. MTG16a was the only MTG protein capable of nuclear-cytoplasm shuttling (Figure 3c ). Because we have not analysed the MTG16a-heterokaryons by time-lapse imaging, we do not know whether the nuclear dots that we observed in the mouse nucleus (Figure 3c ) would eventually organize into a nucleolus. On the other hand, our observation could also reflect the phenomenon of nucleolar dominance, already described in human/rodent heterokaryons (Pikaard, 2000) .
We observed that MTG16a could co-localize with both the nuclear HDAC1 and HDAC3, but not with the nuclear HDAC4. Again the interaction resulted in colocalization of MTG16a-HDACs complexes in the nucleolus. Differently from the mETO2, MTG16a did not interact with the cytoplasmic HDAC6 (Amann et al., 2001 ) indicating a possible functional difference between the murine and human MTG16 proteins.
So far our data show that MTG16a is capable of multiple protein -protein interactions, both with other MTG proteins as well as HDACs, possibly forming complexes implicated in the repressive regulation/ silencing of nucleolar DNA. Repression of nucleolar DNA, like rDNA, was first suggested in relationship to the phenomenon of 'nucleolar dominance' (Pikaard, 2000) and recently invoked to explain the existence of active and inactive nucleolar rDNA regions in mature nucleoli (Sullivan et al., 2001 ). We do not have any direct evidence that MTG16a may be involved in silencing of nucleolar DNA. However, it may be noteworthy that MTG16a is often found at the periphery of nucleoli in characteristic rings ( Figure  1g ). Interestingly, large arrays of inactive methylated rDNA repeats are also found clustered in perinucleolar chromatin rings (Akhmanova et al., 2000) . DNA methylation and histone deacetylation have been shown to be involved in the control of rDNA silencing (Pikaard, 2000; Santoro and Grummt, 2001) . It is therefore plausible that nucleolar corepressors, like MTG16a, are capable of mediating rDNA silencing.
In most t (16; 21)-positive malignant cells, AML1 replaces the entire N-terminal MTG16 region necessary for nucleolar targeting and is co-expressed with the wild-type MTG16 (Gamou et al., 1998) . The loss of the N-terminal region, as well as the acquisition of the AML1-DNA binding domain, are both likely explanations for the nucleoplasmic localization of the chimeric protein (Figure 5a ). We found that when MTG16a was co-expressed with AML1-MTG16 it co-localized with the chimeric protein in the nucleoplasm as a consequence of protein interaction (Figure 5b ). These data suggest that the (16; 21)-translocation can cause a deficiency of MTG16a in the nucleolus and its accumulation in the nucleoplasm at AML1-MTG16 sites. Since AML1-MTG16 can form complexes with HDAC1 and HDAC3 in the nucleoplasm (Figure  5d ,e), it is expected that genes normally transcription- ally activated by AML1 be repressed by AML1-MTG16. Moreover, the deficiency of MTG16a in the nucleolus might lead to transcriptional activation of rDNA and increased cell proliferation (Pikaard, 2000; Zhai and Comai, 2000) .
We expect that the identification of the genes repressed by MTG16a-HDAC complexes in the nucleolus will advance our knowledge of the epigenetic control of nucleolar transcriptional regulation/silencing, which were anticipated many decades ago by Barbara McClintock (McClintock, 1934) as well as the role of MTG16a in the pathogenesis of t (16; 21)-positive myeloid malignancies.
Materials and methods
Cells and culture conditions
COS-7, HeLa, rat mesencephalic CSM14.1 (Evert et al., 1999) cells and human fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% Fetal Calf Serum (FCS) and 1% antibiotics (penicillin/ streptomycin). The t (8; 21) containing cell line Kasumi-1 (Asou et al., 1991) , the K-562, KG-1a and HEL cell lines were cultured in RPMI medium supplemented with 10% (FCS) and antibiotics. Antibodies MTG8 (AB-8), MTG16 (AB-16) and MTGR1 (AB-R1) specific antibodies were developed using unique synthetic peptides for MTG8 (RQQSPVNPDPVALDAHREFLHR-PASGYVP), MTG16 (GPTAVVADPVPGPPEAA), MTGR1 (CVGRGSSARSADCSVPSPAL). Other antibodies were obtained from commercial sources and included goat anti-B23 (AB-23), mouse anti-Cytokeratin 18, mouse antip53, goat anti-AML1 (AB-AML) (Santa-Cruz Biotechnology), mouse anti-V5 (AB-V5) (Invitrogen), FITC-antiPhalloidin (Molecular Probes), mouse anti-GFP (AB-GFP) (Roche) and mouse anti-FLAG M2 (Sigma).
Primers
We used the primers listed below with our lab reference number, orientation (f=forward; r=reverse), sequence, position relative to specific cDNA sequences identified by the GI accession number:
Plasmids
MTG8a cDNA was kindly provided by Dr K Shimizu (Tokyo, Japan), MTG16a was kindly provided by Drs Kosoda and Ohki (Tokyo, Japan), MTG16b was kindly provided by Dr R Schillace (Portland, OR, USA) and MTGR1a, AML1-MTG8 and AML1-MTG16 type1 cDNA's were kindly provided by Dr I Kitabayashi (Tokyo, Japan). The cDNA's were cloned into pcDNA3.1/V5-His TOPO vector (Invitrogen). MTG8b was cloned into the CMVGateway vector. MTG16a was also cloned into the pLNCX2 vector (Clontech) and the pcDNA3.1/CT-GFP-TOPO vector (Invitrogen). FLAG-tagged HDAC1, HDAC3, HDAC4 and HDAC6, all cloned in the pcDNA3.1 vector (Invitrogen), were kindly provided by Dr E Verdin (San Francisco, OA, USA).
Transient transfection
Different plasmid cDNAs (1 mg) were transfected using Lipofectamine Plus (Invitrogen). Two days after transfection cells were harvested by trypsinization. Harvested cells were used either for SDS -PAGE and Western blotting (WB) or immunoprecipitation (IP). For time-lapse imaging experiments, COS cells were transfected with 300 ng DNA and cultured on coverslips in a chamber in a heated microscope stage at 378C with 5% CO 2 .
Immunocytochemistry (IC)
Transfected cells were fixed and incubated with the appropriate primary antibody. The secondary antibodies labeled either with FITC (green) or TRITC (red) were used for detection. Nuclei were counter-stained with DAPI (blue).
Interspecies heterokaryon assay
This assay was performed essentially as described (GuiochonMantel et al., 1991) . Briefly, HeLa cells transfected with the cDNA of choice were seeded with an equal number of NIH 3T3 mouse cells in DMEM containing 200 mg/ml of cycloheximide (Sigma) fused with polyethylene glycol (PEG Mol.Wt.3000-3700, Sigma). Cells were analysed by immunocytochemistry (IC) with different combinations of ABs including anti-Cytokeratin or anti-Phalloidin, AB-8, AB-16, AB-p53, and AB-V and appropriate secondary ABs labeled with FITC or TRITC (Molecular Probes). The Hoechst stain was added at a final concentration of 1 mg/ml to the secondary ABs and images were analysed.
Immunoprecipitation (IP)
Cell extracts in a HEPES buffer pH 8.0 (20 mM HEPES, 1.2M KCl, 5 mM EDTA, 0.5% Triton X100, 0.05% Tween 20) with the addition of a protease inhibitors cocktail (Complete, from Boehringer Mannheim) (Buffer A) were diluted seven times in Buffer A without KCl and pre-cleared with Protein A Sepharose (Sigma). Antibodies were added to the samples at 1 : 200 dilution and immune-complexes were isolated with Protein A Sepharose. Samples were analysed on SDS -PAGE followed by Western blotting.
SDS -PAGE and Western blotting
Protein samples were separated on size by SDS -PAGE followed by electroblotting onto nitrocellulose membrane (Schleicher and Schuell). Immunodetection was performed with rabbit polyclonal AB-8 (1 : 4000), AB-16 (1 : 2000) , AB-R1 (1 : 2000) , mouse monoclonal AB-V5 (1 : 5000) and AB-GFP (1 : 1000) and secondary anti-rabbit and anti-mouse ABs, coupled to peroxidase (1 : 5000) by chemiluminescence (ECL KIT, Amersham). Stripping (the complete removal of primary and secondary antibodies) and re-probing of the blots was performed following the manufacturer's protocol (ECL Western blotting protocols, Amersham Life Science).
RT -PCR
DNase treated total RNA was reverse transcribed and amplified using the Superscript One Step RT -PCR System (Invitrogen) and specific primers for MTG8a (6165+6274), MTG8b (5803+6274), MTG16a (7140+6675), MTGR1a (6281+6740) and AML-MTG8 (6678+6274).
MTG16a deletion mutants
MTG16D1 and MTG16D2 were developed by amplifying MTG16a cDNA either with primers 6278+6280 (MTG16D1) or 01R0775+6280 (MTG16D2) and cloning into the pcDNA3.1/V5/His-TOPO vector. MTG16D2-GFP was amplified with primers 01R0775+01R0666 and subcloned into the pcDNA3.1/CT-GFP-TOPO vector. The D2-GFP construct was developed by PCR-cloning the MTG16a cDNA with primers 7140+2245-102 in-frame with the GFP sequence in the pcDNA3.1/CT-GFP-TOPO vector.
Time lapse imaging
Cells were imaged in six optical planes (thickness 51 mm, 1 mm distance) with a confocal laser-scanning microscope (Zeiss LSM510NLO, Carl Zeiss, Jena, Germany). Up to 15 different locations were imaged sequentially every 15 min for a total of 18 h. GFP transfected cells were excited with a 488 nm laser and emission was measured with a BP 500 -550 filter.
